A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Public ClinicalTrials.gov record NCT02511405. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Study identification
- NCT ID
- NCT02511405
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
- Industry
- Enrollment
- 252 participants
Conditions and interventions
Conditions
Interventions
- Bevacizumab Drug
- VB-111 + bevacizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2015
- Primary completion
- Nov 2, 2017
- Completion
- Sep 29, 2018
- Last update posted
- Oct 22, 2018
2015 – 2018
United States locations
- U.S. sites
- 48
- U.S. states
- 24
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | — | — |
| Highlands Oncology Group | Rogers | Arizona | — | — |
| University of California Irvine Medical Center | Irvine | California | — | — |
| University of California Los Angeles | Los Angeles | California | — | — |
| The Center for Cancer Prevention and Treatment | Orangevale | California | — | — |
| Kaiser Permanente - Redwood City Medical Center | Redwood City | California | — | — |
| University of California | San Diego | California | — | — |
| University of California San Francisco | San Francisco | California | — | — |
| Stanford University | Stanford | California | — | — |
| Colorado Neurological Institute | Denver | Colorado | — | — |
| The George Washington University Medical Faculty Associates | Washington D.C. | District of Columbia | — | — |
| University of Florida Preston A. Wells, Jr. Center for Brain Tumor Therapy | Gainesville | Florida | — | — |
| Orlando Health | Orlando | Florida | — | — |
| Piedmont Physicians Neuro-Oncology | Atlanta | Georgia | — | — |
| Northwestern University | Chicago | Illinois | — | — |
| The University of Chicago | Chicago | Illinois | — | — |
| University of Kansas Medical Center | Kansas City | Kansas | — | — |
| University of Kentucky | Lexington | Kentucky | — | — |
| University of Louisville | Louisville | Kentucky | 40202 | — |
| Louisiana State University Health Science Center | Shreveport | Louisiana | — | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | — | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | — | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | — | — |
| Henry Ford Health System | Detroit | Michigan | — | — |
| Metro-MN Community Oncology Research Consortium | Minneapolis | Minnesota | 55416 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | — | — |
| Dent Neurosciences Research Center | Amherst | New York | — | — |
| North Shore University Hospital | Lake Success | New York | — | — |
| Columbia University Medical Center | New York | New York | — | — |
| Derald H. Ruttenberg Treatment Center | New York | New York | — | — |
| University of Rochester Medical Center | Rochester | New York | — | — |
| Stony Brook University, Neurology Associates of Stony Brook | Stony Brook | New York | — | — |
| SUNY Upstate Medical University | Syracuse | New York | — | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | — | — |
| Wake Forest Baptist Medical Center | Winston-Salem | North Carolina | — | — |
| Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania | — | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | — | — |
| Texas Oncology-Austin Midtown | Austin | Texas | 78705 | — |
| Baylor Health Neuro-Oncology Associates | Dallas | Texas | — | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | — | — |
| : University of Texas, HSC | Houston | Texas | — | — |
| MD Anderson | Houston | Texas | — | — |
| UTHSCSA | San Antonio | Texas | — | — |
| Huntsman Cancer Institute at The University of Utah | Salt Lake City | Utah | — | — |
| University of Virginia | Charlottesville | Virginia | — | — |
| Swedish Medical Center | Seattle | Washington | — | — |
| University of Wisconsin | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02511405, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2018 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02511405 live on ClinicalTrials.gov.